Relay Therapeutics Inc (RLAY)
Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on improving small-molecule drug discovery for targeted oncology and genetic disease applications. Its development pipeline includes RLY-2608, a PI3K alpha inhibitor being studied for breast cancer, solid tumors, and vascular malformations, as well as an alpha-galactosidase chaperone program for Fabry disease. The company is also developing RLY-8161, a RAS-family oncology candidate, and lirafugratinib (RLY-4008), a receptor tyrosine kinase program for cancer. Relay Therapeutics has collaboration and license agreements with D. E. Shaw Research, Elevar Therapeutics, and Pfizer to support research and development activities. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company was formerly known as Allostery, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RLAY
|
$11.40
|
-42.0% Downside
|
Overvalued
|
$26.08
|
32.7% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-15.7x
|
6.7x
|
401.3x
|
4.18 B
|
3.674 B
|
0.7%
|
71.1%
|
39.2
|
—
|
78.2%
|
